PH

Piper Heartland Healthcare Capital

North America, Minnesota, United States, Minneapolis

Description

Piper Heartland Healthcare Capital is a buyout fund managed by Piper Sandler.

Investor Profile

Piper Heartland Healthcare Capital has made 14 investments, with 5 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (50%)
  • Series B (29%)
  • Series A (7%)
  • Series D (7%)
  • Series Unknown (7%)

Country Focus

  • United States (93%)
  • Switzerland (7%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science
  • Oncology
  • Biopharma
  • Pharmaceutical
  • Apps
  • Artificial Intelligence (Ai)
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Piper Heartland Healthcare Capital frequently co-invest with?

Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 4
Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 5
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 6
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 5
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 6
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 4
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 4
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 4
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 4

Which angels does Piper Heartland Healthcare Capital often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Piper Heartland Healthcare Capital?

Arbor Biotechnologies

Cambridge, Massachusetts, United States

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

BiopharmaBiotechnologyLife Science
Series CMar 18, 2025
Amount Raised: $73,900,000
Saluda Medical

Bloomington, Minnesota, United States

Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions.

Health CareMedicalMedical DeviceTherapeutics
Series UnknownJan 10, 2025
Amount Raised: $100,000,000
Alentis Therapeutics

Allschwil, Basel-Landschaft, Switzerland

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

BiotechnologyManufacturingPharmaceuticalTherapeutics
Series DNov 12, 2024
Amount Raised: $181,400,000
AvenCell

Watertown, Massachusetts, United States

Based on our deep science and focused on patients in need.

Health Care
Series BOct 22, 2024
Amount Raised: $112,000,000
Endeavor BioMedicines

Solana Beach, California, United States

Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.

BiotechnologyHealth CareMedical
Series CApr 24, 2024
Amount Raised: $132,500,000
Alumis

San Francisco, California, United States

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

BiotechnologyHealth CareLife SciencePrecision Medicine
Series CMar 6, 2024
Amount Raised: $259,000,000
ProfoundBio

Seattle, Washington, United States

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

BiotechnologyOncologyTherapeutics
Series BFeb 13, 2024
Amount Raised: $112,000,000
Bicara Therapeutics

Cambridge, Massachusetts, United States

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

BiopharmaBiotechnologyLife ScienceOncologyTherapeutics
Series CDec 12, 2023
Amount Raised: $165,000,000
Avalyn Pharma

Seattle, Washington, United States

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series CSep 27, 2023
Amount Raised: $175,000,000
Boundless Bio

La Jolla, California, United States

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

BiotechnologyHealth CareLife ScienceOncologyTherapeutics
Series CMay 16, 2023
Amount Raised: $100,000,000